Bausch Health Companies Inc.
Financials
Valuation Metrics
Bausch Health Companies Inc.'s Market Cap is $3.07B. At end of 2025 it was $2.58B. Ranked #1635 of 3,116 in US market (top 52%), #1061 of 1,644 on NYSE (top 65%), #95 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 36%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.07B | US#1,635/3,116 Sec#95/265 |
| Revenue | $10.85B | US#533/3,116 Sec#19/265 |
| Net Income | $-1.10B | US—/3,116 Sec—/265 |
| Total Assets | $24.79B | US#539/3,116 Sec#21/265 |
| Net Assets | $-1.77B | US#3,051/3,116 Sec#263/265 |
| Employees | 20,300 | US#543/3,116 Sec#19/265 |
| Value | ||
| P/S | 0.28x | US#175/3,116 Sec#2/265 |
| EV/EBITDA | 10.76x | US#935/3,116 Sec#30/265 |
| FCF Yield | 45.41% | US#49/3,116 Sec#3/265 |
| Profitability | ||
| ROA | -4.43% | US#2,497/3,116 Sec#87/265 |
| Op. Margin | 25.44% | US#657/3,116 Sec#34/265 |
| Revenue Growth | 10.09% | US#1,232/3,116 Sec#97/265 |
| Earnings Growth | -1220.41% | US#1,999/3,116 Sec#68/265 |
| Financial Health | ||
| Total Debt | $20.78B | US#225/3,116 Sec#15/265 |
| FCF | $1.39B | US#469/3,116 Sec#23/265 |
| Cash | $1.82B | US#440/3,116 Sec#20/265 |
| Current Ratio | 1.44x | US#1,726/3,116 Sec#238/265 |
| Net Debt/EBITDA | 9.26x | US#2,341/3,116 Sec#82/265 |
| Performance | ||
| 1Y Return | 24.21% | US#496/3,116 Sec#72/265 |
| 1M Return | 40.82% | US#16/3,116 Sec#5/265 |
| From 52W High | -9.18% | US#181/3,116 Sec#16/265 |
| 1Y MDD | -43.92% | US#2,123/3,116 Sec#140/265 |
| Trading | ||
| Volume | 8,044,499 shares | US#62/3,116 Sec#4/265 |
| Trading Value | $68M | US#552/3,116 Sec#24/265 |
| Per Share | ||
| EPS | $-2.94 | US—/3,116 Sec—/265 |
| BPS | $-4.74 | US—/3,116 Sec—/265 |
Company Info
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.